Introduction {#Sec1}
============

COVID-19, the novel coronavirus infection started from Wuhan, China in December 2019. The outbreak was declared a public health emergency of international Concern on 30 January 2020 and later a pandemic on March 11, 2020 by World Health Organization (WHO) \[[@CR1]\]. It is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus belongs to the β-Coronavirus family and is partially like the SRS-CoV and MERS-CoV coronaviruses which have caused previous epidemics in China and Middle East respectively \[[@CR2]\]. The management of the disease is challenging as the virus is highly infectious and there is a large burden of asymptomatic patients, absence of proven antiviral drugs, and limited understanding of potential benefits from antiviral antibodies \[[@CR3]\].

Severe Acute Respiratory Distress Syndrome (ARDS), in addition progression to multi-organ dysfunction syndrome has been recognized as cause of death in most of the patients. ARDS is common amongst patients needing hospitalization, which comprise around 20% of all infected patients \[[@CR4]\]. The exact mechanism of pulmonary complications and ARDS of COVID-19 has not been elucidated but there is a clear component of thrombo-inflammation and cytokine storm \[[@CR5], [@CR6]\].

Irrespective of the cause of sepsis, coagulopathy is consistently associated with poor prognosis \[[@CR7]\] and this has been postulated for COVID-19 as well. Multiorgan dysfunction is likely in coagulopathy in patients with sepsis and leads to increased mortality. Multiple reports have reported the presence of deranged parameters of coagulation in patients of COVID-19. In this review, we will discuss the various pathophysiological mechanisms leading to COVID-19 associated coagulopathy (CAC), derangement in laboratory parameters, incidence, and risk factors of venous thromboembolism (VTE) and prevention and treatment of CAC.

Pulmonary Intravascular Coagulation, its Histopathological Evidence and Contribution of Cytokine Storm {#Sec2}
======================================================================================================

COVID-19 patients have been shown to have high levels of D-dimer \[[@CR8], [@CR9]\] but unlike patients of sepsis, they only have a mild prolongation of prothrombin time (PT), activated partial thromboplastin time (APTT), mild thrombocytopenia \[[@CR4], [@CR9]\]. The first histopathology report was incidental in two lung cancer patients with unsuspected COVID-19. Lung histopathology revealed only early findings seen in COVID-19 including alveolar damage with proteinaceous alveolar exudates and edema, vascular congestion, and focal fibrin deposition with pneumocyte hyperplasia \[[@CR10]\]. These findings suggested that pulmonary coagulopathy starts early in the disease itself. Mortality has been reported right from the beginning but the autopsy data from COVID-19 patients has lagged. Till date, very few studies on histopathological findings are available \[[@CR11]--[@CR15]\].

Autopsy data suggests that there is exudative diffuse alveolar damage with severe capillary congestion. In addition, the frequent findings include edema, alveolar hemorrhage, pulmonary embolism and microthrombi in the alveolar capillaries \[[@CR11]\].

These findings were aptly described by McGonagle as Pulmonary intravascular coagulation (PIC) with the suggestion that it arises due to macrophage activation syndrome (MAS)-like intrapulmonary inflammation that causes vessel wall damage \[[@CR16]\]. This PIC is mediated by a thrombo-inflammation. SARS-CoV2 infects the type II pneumocytes via angiotensin converting enzyme 2 (ACE-2) receptors eliciting a phenomenon culminating in PIC (Fig. [1](#Fig1){ref-type="fig"}). Due to the widespread presence of ACE-2 receptor in the lung, there is a damage to large surface area of the alveoli leading to hypoxemia. In addition, there is extensive vascular damage due to juxtaposition of type II pneumocytes to the vessels. The infection also causes a massive cytokine storm. There is increased expression of tissue factor on endothelium and inflammatory cells including neutrophils and macrophages. There is extensive endothelial injury and dysfunction partly due to cytokines such as interleukin (IL)-1, IL-6 and tumour necrosis factor-α as well as an intra-pulmonary MAS-like inflammation. These phenomena ultimately lead to intrapulmonary activation of coagulation cascade. Inflammatory reaction also caused a reduced level of plasminogen activator inhibitor-1 (PAI-1) causing increased level of plasmin. There is both a component of intrapulmonary thrombosis, microhemorrhages and hyperfibrinolysis. Plasmin and other proteases can also cleave a furin site in the S protein of SARS-CoV 2 leading to increased virulence of the virus. Thrombosis observed is primarily intra-pulmonary but can progress to systemic thrombosis in a subset of patients. The combination of thrombosis and inflammation cause a positive feedback loop exacerbated by local hypoxia \[[@CR16]\].Fig. 1Pathogenesis of pulmonary intravascular coagulopathy (PIC) and thrombosis

Magro et al. \[[@CR12]\] examined skin and lung tissues from 5 patients. According to them, the pattern of COVID-19 pneumonitis was predominantly a pauci-inflammatory septal capillary injury with significant septal capillary mural, luminal fibrin deposition and permeation of the interalveolar septa by neutrophils. No viral cytopathic changes were observed and the diffuse alveolar damage (DAD) with hyaline membranes, inflammation, and type II pneumocyte hyperplasia, the hallmarks of classic ARDS were not prominent. Significant deposits of terminal complement components C5b-9 (membrane attack complex), C4d, and mannose binding lectin (MBL)-associated serine protease (MASP), in the microvasculature were seen consistent with sustained, systemic activation of the alternative and lectin-based complement pathways. Purpuric skin lesions similarly showed a pauci-inflammatory thrombogenic vasculopathy, with deposition of C5b-9 and C4d. There was co-localization of COVID-19 spike glycoproteins with C4d and C5b-9 in the interalveolar septa and the cutaneous microvasculature \[[@CR12]\].

Histological similarities were observed between COVID 19 and SARS 2002--2003. Localized pulmonary hemorrhage, pulmonary edema, desquamation with hyaline membrane formation and an interstitial mononuclear inflammatory infiltrate were seen. Localized pulmonary arteriolar thrombosis was seen with SARS but not with COVID-19 \[[@CR13]\].

Wichmann and colleagues described autopsy findings in 12 COVID-19 patients revealing deep venous thrombosis (DVT) in 7 of 12 unsuspected patients (58%). Pulmonary embolism (PE) was the direct cause of death in 4 patients. Histologically, DAD was seen in 8 patients. In all patients, SARS-CoV-2 RNA was detected in lungs at high concentrations; viremia in 6 of 10 and 5 of 12 patients demonstrated high viral RNA titers in the liver, kidney, or heart \[[@CR14]\]. Immunohistochemistry done on lung specimens revealed thickened alveolar capillaries with edema and fibrin thrombi. There were CD61 and von Willebrand factor (vWF) positive resident pulmonary megakaryocytes in alveolar capillaries that exhibited nuclear hyperchromasia and atypia \[[@CR15]\].

Coagulation Abnormalities {#Sec3}
=========================

Overall COVID-19 is associated with a hypercoagulable state with DIC setting in only in late cases. Coagulation anomalies and clinical features observed in COVID-19 associated coagulopathy are different from DIC (Fig. [2](#Fig2){ref-type="fig"}). DIC can complicate the course of disease with reported incidence of 71.4% in non-survivors when compared to only 0.6% survivors \[[@CR8]\]. While DIC predominantly presents with generalized derangement of coagulation and bleeding manifestations, CAC has specific alterations in these coagulation parameters that differ from DIC and clinical bleeding is uncommon.Fig. 2Differences between COVID-19 coagulopathy from disseminated intravascular coagulation

Platelet Pounts (PC) {#Sec4}
--------------------

Thrombocytopenia has been observed in \~ 18--36% of hospitalized patients with COVID-19 but is usually not severe \[[@CR9], [@CR17], [@CR18]\]. PC of \< 100 × 10^9^/L is seen in only 5% COVID-19 patients \[[@CR4]\]. COVID-19 patients have a higher platelet count than non-COVID patients \[[@CR19]\]. This is unlike sepsis where thrombocytopenia is an indicator of mortality due to sepsis \[[@CR20]\]. Thrombocytopenia at threshold of 125X10^9^/L was observed more frequently in COVID-19 non-survivors \[[@CR17], [@CR18]\].

This thrombocytopenia is multi-factorial in etiology including cytokine storm, possible direct cytopathic effect on marrow, immune mediated clearance of platelets due to formation of anti-platelet antibodies and lung injury causing platelet activation and consumption and lastly alteration of pulmonary capillary bed causing reduced lung megakaryocyte fragmentation and platelet production \[[@CR21]\].

Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), Fibrinogen and D-Dimer {#Sec5}
-------------------------------------------------------------------------------------------

Initial studies reported mild prolongation of PT in patients with severe disease requiring ICU admission and mortality \[[@CR4], [@CR8], [@CR9]\]. It is important to remember that these mild prolongations may be missed if PT is expressed as PT ratio or PT% rather than in seconds \[[@CR8]\], as probably happened in studies when data was reported in these formats \[[@CR22], [@CR23]\]. APTT values did not correlate with severity of disease in most studies. Most consistent data reported was for D-dimer \[[@CR4], [@CR8], [@CR9], [@CR24], [@CR25]\]. Elevated D-dimer value at admission is a predictor for both severity of COVID-19 \[[@CR4], [@CR9], [@CR24]\] and mortality \[[@CR8], [@CR25], [@CR26]\]. Various cut-offs have been determined to predict a higher risk of death in COVID-19 \[[@CR25], [@CR26]\] and for venous thromboembolism (VTE) \[[@CR27]\]. The role of D-dimer to predict disease outcome was subsequently confirmed in a meta-analysis \[[@CR28]\]. It is important to note that since D-dimer elevations in these hospitalized patients are not accurate predictor of subsequent VTE. The sensitivity, specificity and negative predictive value of elevated D-dimer at levels of ≥ 1.5 µg/mL that predicted VTE were 85%, 88.5% and 94.7% respectively \[[@CR27]\]. It is important to note that all the coagulation tests have been performed on different equipments using proprietary reagents and hence, cut-offs generated will have to be validated at each center. Table [1](#Tab1){ref-type="table"} discusses the role of D-dimer and Table [2](#Tab2){ref-type="table"} reflects the other routine coagulation parameters in COVID-19 patients. Fibrinogen is generally normal or elevated \[[@CR29], [@CR30]\] in these patients with a reduction in values reported only late in the course of disease when DIC sets in some patients \[[@CR8]\].Table 1Correlation of D-dimer with mortality and severe diseasePatients (n)Severe versus non-severe diseaseNon-survivors versus survivorsAdditional findingsTang et al. \[[@CR8]\]183 (134 non-survivors)NR2.12 µg/mL (0.77--5.27) versus 0.61 µg/mL (0.35--1.29) versus *p* \< 0.001Incidence of DIC-71.4% in non-survivors versus 0.6% in survivorsHuang et al. \[[@CR4]\]41 (13 in ICU)2.4 mg/L; (IQR 0.6--14.4 mg/L) versus 0.5 mg/L; (IQR 0.3--0.8 mg/L; *p* *=* 0.004)NRWang et al. \[[@CR24]\]138 (36 in ICU)4.14 mg/L; (IQR 1.91--13.2 mg/L) versus 1.66 mg/L; (IQR 1.01--2.85 mg/L; *p* \< 0.001)NRZhou et al. \[[@CR25]\]191 (54 non-survivors)NR5.2 mg/L; (IQR 1.5--21.1 mg/L) versus 0.6 mg/L; (IQR 0.3--1.0--mg/L); *p* \< 0.001D-dimer ≥ 1.0 µg/mL: 81% non-survivors versus 24% survivors; *p* \< 0.0001 and had a multivariable odds ratio of 18.42 (*p* *=* 0.003) to predict mortalityZhang et al. \[[@CR26]\]343 (13 non-survivors)NR4.76 µg/mL (2.99--11.9) versus 0.41 µg/mL (0.15--0.69); *p* \< 0.001D-dimer ≥ 2.0 µg/mL at admission had a sensitivity of 92.3% and specificity of 83.3% to predict mortality; Hazard ratio: 51.5, 95% CI 12.9--206.7Middeldorp et al. \[[@CR23]\]198 (75 in ICU)2.0 mg/L (0.8--8.1) versus 1.1 mg/L (0.7--1.6), *p* *=* 0.006*NR* not reported, *VTE* venous thromboembolism, *IQR* inter quartile rangeTable 2Correlation of PT^a^, APTT^a^ with severity of COVID-19Patients (n)Severe versus non-severe diseaseNon-survivors versus survivorsAdditional findingsTang et al. \[[@CR8]\]183 (134 non-survivors)NRPT: 15.5 (14.4--16.3) versus 13.6 (13.0--14.3), *p* *=*  \< 0.001APTT 44.8 (40.2--51.0) versus 41.2 (36.9--44.0), *p* *=* 0.096Fibrinogen and AT declined in non-survivors by day 10 and 14; also day 7 for ATExpression of PT results as PT ratio miss the significanceHuang et al. \[[@CR4]\]41 (13 in ICU)PT: 12·2 (11·2--13·4) versus 10·7 (9·8--12·1), *p* *=* 0.012NRWang et al. \[[@CR24]\]138 (36 in ICU)PT: 13.2 (IQR 12.3--14.5) versus 12.9 (IQR 12.3--14.5); *p* 0.37APTT: 31.7 (IQR 29.6--33.5) versus 30.4 (IQR 28.0--33.5), *p* *=* 0.09NRZhou et al. \[[@CR25]\]191 (54 non-survivors)NRPT: 12.1 s (IQR 11.2--13.7) versus 11.4 (IQR 10.4--12.6) *p* \< 0.0004PT ≥ 16 s seen in in 3% survivors versus 13% non-survivors, *p* *=* 0.016 but lost significance on multivariable analysisCui et al. \[[@CR27]\]81 (20 had VTE)NRNRAPTT values in VTE significantly higher than patients without VTE*AT* antithrombin, *NR* not reported, *VTE* venous thromboembolism, *IQR* inter quartile range^a^PT and APTT values reported in seconds

Viscoelastic Tests and a Procoagulant State {#Sec6}
-------------------------------------------

The levels of Antithrombin (AT) have been found to be marginally reduced in COVID-19 patients compared to controls \[[@CR31]\]. AT values decline in non-survivors by Day 7 when compared to survivors \[[@CR8]\]. Factor VIII, vWF and vWF ristocetin cofactor activity (vWF-RCoF) were evaluated in 11 patients and were increased at levels of 297 U/dL(233--470), 529 U/dL(210--863) and 387 U/dL(195--550) respectively indicating possible endothelial dysfunction due to sepsis. In the same patient subset, AT and free protein S levels were marginally decreased while protein C was increased \[[@CR30]\].

Limited studies on viscoelastic testing have shown a procoagulant profile rather than acute DIC in patients with COVID-19 (Table [3](#Tab3){ref-type="table"}) \[[@CR22], [@CR29], [@CR30]\]. This hypercoagulability may be attributed to endothelial dysfunction, elevated circulating platelet microparticles, neutrophil extracellular traps (NETs) and elevated inflammatory cytokines \[[@CR30]\]. The impact of thromboprophylaxis to normalize the hypercoagulable state seen using the viscoelastic tests has largely not been documented. Only one of the studies that utilized the Quantra^®^ hemostasis analyser where increasing thromboprophylaxis led to a reduction in the increased values of clot strength (CS), platelet contribution to clot strength and fibrinogen contribution to clot strength (FCS) \[[@CR29]\]. However, only data from less than 100 patients in total has been reported in patients using various forms of viscoelastic testing \[[@CR22], [@CR29], [@CR30]\]. It remains to be seen whether doing viscoelastic testing at baseline at the time of testing can identify patients who might go on to develop severe disease or thrombosis. The role of viscoelastic testing on management of thromboprophylaxis in COVID-19 patients should be studied further.Table 3Viscoelastic tests in COVID-19StudyNo. of patientsTechniqueKey findingsSpiezia et al. \[[@CR22]\]22 ICU patientsROTEM with INTEM, EXTEM and FIBTEMSignificantly shorter CFT in INTEM and EXTEMSignificantly higher MCF in INTEM, EXTEM and FIBTEMRanucci et al. \[[@CR29]\]16 ICU patientsQuantra Hemostasis analyser using Quantra QPlus^®^ cartridgeIncreased CS, PCS, FCS in COVID-19 patients increasing thromboprophylaxis caused reduction in CS, PCS and FCSPanigada et al. \[[@CR30]\]30 results from 24 ICU patientsTEG with kaolin as activator and heparinaseR and K values were shorter in 50% and 83% while K angle and MA were increased in 72% and 83% patients when compared to local reference, decreased Lys30*ROTEM* rotational thromboelastometry, *CFT* clot formation time, *MCF* maximal clot firmness, *CS* clot strength, *PCS* platelet contribution to clot strength, *FCS* fibrinogen contribution to clot strength, *TEG* thromboelastography, *MA* maximal amplitude

Antiphospholipid Antibodies (aPL) and Lupus Anticoagulant (LA) {#Sec7}
--------------------------------------------------------------

A report of three critical cases from China with aPL antibodies was published by Zhang et al. All the patients had a comorbid condition that predisposed them to severe disease and developed cerebral infarcts. Anticardiolipin (aCL) IgA antibodies and anti-β2 glycoprotein-I IgA and IgG antibodies were reported in all patients but were negative for lupus anticoagulant (LA) \[[@CR32]\]. It was interesting that in this case report, IgA antibody testing was performed for both aCL and anti-β2 glycoprotein-I antibodies which are not a part of the diagnostic criteria for antiphospholipid syndrome \[[@CR33]\] while the data on aCL IgG and IgM and anti-β2 glycoprotein-I IgM antibodies is not reported. A series from France on 56 COVID-19 patients reported 45% positivity for LA while aCL and anti-β2 glycoprotein-I (IgG/IgM) were seen in 10%. Three patients were positive for both LA and one of the antiphospholipid antibodies tested \[[@CR34]\]. This study has however, not reported data on thrombosis. In addition, it has not been mentioned whether DRVVT and LA sensitive PTT were performed before starting anticoagulant prophylaxis or not.

Clinical Thrombosis {#Sec8}
===================

As a result of CAC, patients of COVID-19 have been observed to have higher incidence of thrombosis including both VTE (DVT and PE), central venous catheter/arterial line associated thrombosis, thrombosis of extracorporeal circuits for continuous veno-venous hemofiltration (CVVH) and extracorporeal membrane oxygenation (ECMO). The diagnosis of PE is challenging in these patients as symptoms of PE overlap with COVID-19. PE should be suspected if there is acute worsening of hypoxemia, blood pressure or tachycardia, and/or oxygen requirement and ventilatory settings are disproportionate to the severity of pneumonia on chest imaging. Even the diagnosis of DVT is difficult as the focus of care is on the respiratory system while the patients are in the ICU and the signs of DVT in the extremities may be missed. In addition, great amount of hospital resource is utilized in shifting these sicker patients to radiology units for carrying out computed tomography pulmonary angiogram (CTPA) and doppler ultrasound (USG) with associated risk of exposure and aerosolization The major contributory factors to thrombosis, in addition to those described above in pathology and prothrombotic state include ICU stay, central lines, CVVH, ECMO, limited mobility, comorbidities etc.

In most studies published evaluating symptomatic or asymptomatic VTE, overwhelmingly patients were from ICU and most of them were on prophylactic doses of LMWH (Table [4](#Tab4){ref-type="table"}). Some studies have also included general ward patients, while some have screened for VTE in asymptomatic patients. As a result, incidence of symptomatic VTE is variable across studies. Llitjos et al. showed that incidence of thrombosis was lower if therapeutic doses of anticoagulation was used as prophylaxis (56% vs 100% respectively, *p* *=* 0.03) \[[@CR35]\]. The 28-day mortality of heparin users were lower than nonusers in COVID-19 group with D-dimer \> 3.0 μg/mL (32.8% vs 52.4%, *p* *=* 0.017) \[[@CR19]\]. This suggests that even therapeutic anticoagulation is insufficient in some of these patients in the face of CAC.Table 4Proven thrombosis in COVID patientsNo of patients (n)ProphylaxisIncidence of VTE, arterial thrombosisKey findingsKlok et al. \[[@CR36]\]184 ICU patientsNadroparin27% (95% CI 17--37) VTE. 3.7% (95% CI 0--8.2%) arterialPE common. Age (aHR 1.04), coagulopathy (aHR 4.1) are predictors of thrombosisLlitjos et al. \[[@CR35]\]26 ICU patientsYes69%, (23% PE)Prophylaxis versus therapeutic (100% vs 56%, respectively, *p* *=* 0.03)Middeldorp et al. \[[@CR23]\]198 (75 in ICU)Nadroparin20% (13% symptomatic)ICU stay versus ward (47%, 95% CI 36--58 vs 3.3%, 95% CI 1.3--8.1), higher WBC count, higher neutrophil--lymphocyte ratio, D-dimer were risk factors. Incidence increased with duration of hospital stayLodigiani et al. \[[@CR37]\]388 (61 in ICU)All in ICU, 75% in ward7.7%ICU stay versus ward (16.7% vs 6.4%)Demelo-Rodriquez et al. \[[@CR38]\]156 non-ICU patientsYes14.7%, only 1 proximal DVT, 7 bilateral distalD-dimer levels \> 1570 ng/mL were associated with asymptomatic DVT (OR 9.1; CI 95% 1.1--70.1)Helms et al. \[[@CR39]\]150 ICU patients42.6% (16.7% PE, circuit clots in CRRT and ECMO) \> 95% elevated D-dimer and fibrinogen. No DIC. Higher incidence as compared to non COVID ARDS, mostly PE*VTE* venous thromboembolism, *aHR* adjusted hazard ratio, *DVT* deep vein thrombosis, *PE* pulmonary embolism, *DIC* disseminated intravascular coagulation, *ARDS* acute respiratory distress syndrome, *CRRT* continuous renal replacement therapy, *ECMO* extracorporeal membrane oxygenation

The incidence of thrombosis varies from 7.7--14% in hospitalized patients to as high as 69% in ICU patients. Details are given in Table [4](#Tab4){ref-type="table"}. Various risk factors identified from different studies are age and coagulopathy defined as prolonged PT \> 3 s or APTT \> 5 s \[[@CR36]\]; duration of hospital stay (incidence at day 7, 14 and 21 being 16%, 33% and 42% respectively), ICU versus wards (47% vs 3.3%), higher white blood cell count, higher neutrophil--lymphocyte ratio and a higher D-dimer level \[[@CR23]\]; ICU versus general ward (16.7% vs 6.4%) \[[@CR37]\]; D-dimer levels \> 1570 ng/mL for asymptomatic DVT \[[@CR38]\]. Not surprisingly, VTE has been associated with a higher risk of mortality with a hazard ratio (HR) of 2.7 (95% CI 1.3--5.8) \[[@CR23]\].

Helms et al. \[[@CR39]\] compared 145 non-COVID-19 ARDS patients with 77 COVID-19 ARDS patients and confirmed that latter developed more thrombotic complications, mainly PE (11.7 vs 2.1%, *p* \< 0.008) and deranged coagulation parameters. Griffin et al. \[[@CR40]\] described three patients of arterial thromboembolisms (stroke and popliteal arterial occlusion) in patients with COVID-19, treated with tPA, and/or antiplatelet therapy. Anecdotal reports of arterial thrombosis have also been published \[[@CR32], [@CR36]\].

Possible Therapies {#Sec9}
==================

In this section, we shall discuss about treatment strategies related to coagulopathy only. Considering the high incidence of thromboembolic phenomenon, it is prudent to put all patients admitted to ICU/HDU on thromboprophylaxis. VTE risk assessment tools like Padua prediction model have not been rigorously evaluated in COVID-19 patients. Most recent ISTH guidelines continue to recommend thromboprophylaxis for all hospitalized patients instead of individualized risk assessment tools. The randomized trials are underway, but some of the key published studies available are discussed in Table [5](#Tab5){ref-type="table"}.Table 5Therapeutic interventions undertaken to prevent thrombosisAuthorNumber of patients (n)Medicine under studyResultsTang et al. \[[@CR41]\]449 (99 on LMWH)Heparins versus no heparinNo difference on 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, *p* *=* 0.910). But the 28-day mortality of heparin users were lower than nonusers in patients with SIC score ≥ 4 (40.0% vs 64.2%, *p* *=* 0.029), or D-dimer \> sixfold of upper limit of normal (32.8% vs 52.4%, *p* = 0.017)Testa et al. \[[@CR42]\]32 on DOACsDirectly acting oral anticoagulants (DOACs)C-trough levels were 6.14 times higher during hospitalizationWang et al. \[[@CR43]\]3tPA (alteplase)Transient initial improvement in PaO~2~/FiO~2~ ratio (38--100% improvement)Liu et al. \[[@CR44]\]12DipyridamoleImproved increased platelet and lymphocyte counts and decreased D-dimer levelsDiurno et al. \[[@CR45]\]4EculizumabReduction of C-reactive protein levels and clinical improvement*SIC* sepsis-induced coagulopathy, *tPA* tissue plasminogen activator

Tang and colleagues reported one of the first studies to show benefit of anticoagulation in COVID-19 patients \[[@CR41]\]. Even though day 28 mortality was similar between those on heparin and those without heparin (30.3% vs 29.7%, *p* *=* 0.910), sub-group analysis showed that heparin was able to lower mortality in patients with sepsis-induced coagulopathy (SIC) score ≥ 4 (40.0% vs 64.2%, *p* *=* 0.029) or D-dimer \> sixfold of upper limit of normal (32.8% vs 52.4%, *p* *=* 0.017). Testa et al. \[[@CR42]\] showed \> 6 times higher C-trough levels of Direct acting oral anticoagulants (DOAC), given simultaneously with antivirals. Wang et al. \[[@CR43]\] showed definite but transient improvement without bleeding in ventilatory parameters (PaO~2~/FiO~2~) after treatment with short course of tPA (Alteplase) in ARDS due to COVID-19. Liu et al. \[[@CR44]\] suggested potential benefit of adding dipyridamole. They suggested that dipyridamole can benefit patients by reducing viral replication, suppressing hypercoagulability, and enhancing immune recovery. Relating the pathogenesis to thrombotic microangiopathy, Diurno et al. \[[@CR45]\] showed improved outcome with eculizumab, monoclonal antibody against C5 compliment used in cases of Paroxysmal nocturnal hemoglobinuria.

Choice of anticoagulant is heparin or LMWH during hospital stay. Limited data is available for use of DOACs or warfarin. Heparin could decrease the inflammatory response by blocking thrombin formation. Also, it may possess anti-viral properties by acting on SARS-CoV-2 surface receptor binding proteins and inhibiting viral attachment \[[@CR46]\]. However, major issues with heparin are low antithrombin and high fibrinogen seen in CAC, both known to incur heparin resistance \[[@CR47]\]. This suggests that prophylactic doses of LMWH or UFH could be less efficacious in severe CAC \[[@CR48]\]. Shifting from prophylaxis to therapeutic doses in the absence of proven VTE, although common but is still not based on evidence. It may be considered in patients who are suspected thrombosis but not able to undergo imaging and those on ECMO. Testa et al. \[[@CR42]\] suggested to stop DOAC and shift to heparins due to high drug levels of DOACs when given with antivirals or immunosuppressive therapy. Besides, there are issues of compromised absorption of oral medicine, concurrent renal dysfunction, and difficulty in measuring efficacy in sick ICU patients. They may be considered after discharge, for a total duration of 6 weeks of thromboprophylaxis.

Academic Society Guidelines {#Sec10}
===========================

Several academic societies have come up with guidance for managing CAC. However, they have refrained from providing level of evidence with their recommendations as direct evidence is still lacking and data is evolving.

International society for thrombosis and hemostasis (ISTH) came with interim guidelines in March 2020 on recognition and management of coagulopathy in COVID-19 based on ISTH DIC score \[[@CR49]\]. Similarly, American Society of Hematology (ASH) mentions about management of CAC on its website \[[@CR50]\]. A comparative analysis of these is shown in Table [6](#Tab6){ref-type="table"}. Both guidelines mention about therapeutic LMWH in all hospitalized patients, unless contraindicated by PC or fibrinogen or active bleeding. VTE prophylaxis should be modified in obese or very thin patients and those with renal dysfunction. Patients with obesity should be considered for 50% rise in thromboprophylaxis dosage. Abnormal PT or APTT are not contraindications for pharmacological thromboprophylaxis. Mechanical thromboprophylaxis is recommended when pharmacological thromboprophylaxis is contraindicated. Therapeutic anticoagulation is not required unless VTE or atrial fibrillation is documented. Most of the guidelines are based on the premise that coagulopathy is a risk factor to multi-organ failure in patients with sepsis, so inhibiting thrombin generation is beneficial in reducing mortality \[[@CR51]\]. Current guidelines recommend LMWH as preferred agent during hospitalization and DOAC for post discharge therapy for patients with proven thrombosis. At least three months of treatment is required for these patients \[[@CR52]\].Table 6Comparative analysis of academic society guidelines for COVID thrombosisParameterISTH \[[@CR49], [@CR52]\]ASH \[[@CR50]\]CHEST guidelines \[[@CR56]\]AdmissionProlonged PT, markedly raised D-dimer (≥ 3 ULN), thrombocytopenia (platelet count \< 100 × 10^9^/L) and fibrinogen \< 2.0 g/LNo commentNo commentMonitoringPT, D-dimer, fibrinogenPlatelet count, PT, APTT, D-dimer, and fibrinogenNo commentProphylaxis with LMWHAll patients (including non-critically ill) who require hospitalization. Modification with weight and renal function^a^Recommended for all hospitalized COVID-19 patientsStandard dose LMWH prophylaxis recommended for all acutely ill and critically ill hospitalized patients. Heparins preferredContraindications to prophylaxisActive bleeding and platelet count \< 25 × 10^9^/LActive bleeding, platelet counts \< 25 × 10^9^/L, or fibrinogen \< 0.5 g/LNot specified for COVID-19Transfusion in bleeding patientMaintain platelet count \> 50 × 10^9^/L, fibrinogen \> 2 g/L and PT ratio \< 1.5Transfuse platelets if count \< 50 × 10^9^/L), give plasma if INR \> 1.8 and fibrinogen concentrate or cryoprecipitate if fibrinogen \< 1.5 g/LNo commentTransfusion in non bleeding patientFibrinogen \> 2 g/L and platelet count \> 20 × 10^9^/LNo commentNo commentMechanical thromboprophylaxisWhen pharmacological thromboprophylaxis contraindicated. Can be considered together in sick/immobile patients^b^When pharmacological thromboprophylaxis contraindicatedWhen pharmacological thromboprophylaxis contraindicated. No benefit of adding to pharmaco-prophylaxisTherapeutic anticoagulationLMWH are preferred, duration is minimum 3 monthsVTE and atrial fibrillationLMWH/UFH preferred initially. DOAC/warfarin if no drug interactions. Outpatient with DOAC, warfarin. Minimum 3 months durationExtended anticoagulationLMWH or DOAC for 14--30 days^b^Not advisedScreening for DVTNot needed^b^Not recommended*PT* prothrombin time, *ULN* upper limit of normal, *INR* international normalized ratio, *VTE* venous thromboembolism^b^From new ISTH guidelines (reference)

Principles of blood transfusion are similar to septic coagulopathy with minor differences between guidelines issued by ASH and ISTH. Institution of blood component therapy is not recommended purely based on abnormal laboratory findings without the clinical indication of bleeding or requirement of invasive procedure or in those patients at a high risk of bleeding complications \[[@CR50], [@CR52], [@CR53]\]. American College of Cardiology also advocates a similar policy with respect to thromboprophylaxis in hospitalized patients with COVID-19 and advised for careful assessment for incident thrombotic events. The duration of thromboprophylaxis is 6 weeks like other medical conditions \[[@CR54]\]. Regarding therapeutic doses of anticoagulation for prophylaxis, British Thoracic Society (BTS) advocates risk stratification based on following factors \[[@CR55]\]:Location of patient's care (e.g. critical care).Disease severity (e.g. need for CPAP, high oxygen requirements (e.g. PaO~2~/FiO~2~ ≤ 40 kPa (300 mmHg)), SIC score ≥ 4).D-dimer thresholds (\> 3000 µg/L).Clinical features suggestive of possible VTE.

They also advocate shifting to LMWH if patients were previously on oral anticoagulants during hospital stay. After discharge, thromboprophylaxis should be considered for high risk VTE patients who were hospitalized. BTS suggest DOAC for thromboprophylaxis for upto 4 weeks. However, the recommended duration of post discharge prophylaxis (2 weeks, 4 weeks, or 6 weeks) and choice of agent (whether LMWH or DOAC) are still uncertain.

Recently published CHEST guidelines on CAC provide similar recommendations. They recommend standard dose LMWH as most preferred agent followed by UFH then DOAC for acutely ill and critical hospitalized patients with COVID-19. These guidelines recommend against anti-platelet for thromboprophylaxis and intermediate or full dose of LMWH. Extended thromboprophylaxis should be considered only for patients who are at low risk of bleeding. Mechanical prophylaxis is recommended only for those with contraindication to anticoagulants. For patients who develop VTE, these guidelines suggest initial LMWH (preferred) or UFH followed by continuation of same or shift to dabigatran or warfarin analogues. Thrombolytic therapy is recommended only for acute confirmed PE who show clinical deterioration. For non-hospitalized COVID patients who develop VTE, DOAC are preferred over LMWH for ease of administration and convenience to patients. Warfarin analogues can also be used for these patients after LMWH overlap. Overall duration of anticoagulation treatment should be at least three months \[[@CR56]\].

Conclusions {#Sec11}
===========

COVID-19 associated coagulopathy is associated with high risk of morbidity and mortality and is a cause of concern especially in hospitalized patients. It is multifactorial in nature and manifests with deranged D-dimer, high fibrinogen and is different from DIC with respect to a low occurrence of thrombocytopenia, lack of severe thrombocytopenia, accompanied by only a mild prolongation of prothrombin time and activated partial thromboplastin time. It is important to remember that prothrombin time in these patients should be analyzed in seconds rather than as a ratio or percentage. Both venous and arterial thrombosis appear to be increased especially in sick patients and many of the thromboses may be subclinical in nature. Diagnosing pulmonary embolism in patients in ICU is challenging and high index of suspicion is warranted. Available evidence and guidelines recommend prophylactic anticoagulation with LMWH for all hospitalized patients. Anticoagulant and antiplatelet possibly improve by additional mechanisms (antiviral activity, improving thrombo-inflammation etc.) also in treatment of COVID-19 patients. Most of the available data is not based on randomized controlled trials, which have started recruitment only recently and are expected to guide us further into management of CAC.
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